Masters project on microRNA mechanisms in metabolic diseases

We offer a Masters project on microRNA mechanisms in metabolic diseases starting in Sept 2011.
Santaris Pharma is a biopharmaceutical company that develops innovative RNA-targeted medicines based on its proprietary locked nucleic acid (LNA) drug platform. The Company's LNA oligonucleotide compounds are designed to effectively down-regulate disease-implicated mRNAs and microRNAs.